iPS Cells for Modelling and Treatment of Human Diseases (Record no. 64977)

MARC details
000 -LEADER
fixed length control field 02463naaaa2200301uu 4500
001 - CONTROL NUMBER
control field https://directory.doabooks.org/handle/20.500.12854/50671
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220220042534.0
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783038421221
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783038421214
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title English
042 ## - AUTHENTICATION CODE
Authentication code dc
245 10 - TITLE STATEMENT
Title iPS Cells for Modelling and Treatment of Human Diseases
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. MDPI - Multidisciplinary Digital Publishing Institute
Date of publication, distribution, etc. 2015
300 ## - PHYSICAL DESCRIPTION
Extent 1 electronic resource (422 p.)
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open Access
Source of term star
Standardized terminology for access restriction Unrestricted online access
520 ## - SUMMARY, ETC.
Summary, etc. The field of reprogramming somatic cells into induced pluripotent stem cells (iPSC) has moved very quickly, from bench to bedside in just eight years since its first discovery. The best example of this is the RIKEN clinical trial this year in Japan, which will use iPSC derived retinal pigmented epithelial (RPE) cells to treat macular degeneration (MD). This is the first human disease to be tested for regeneration and repair by iPSC-derived cells and others will follow in the near future. Currently, there is an intense worldwide research effort to bring stem cell technology to the clinic for application to treat human diseases and pathologies. Human tissue diseases (including those of the lung, heart, brain, spinal cord, and muscles) drive organ bioengineering to the forefront of technology concerning cell replacement therapy. Given the critical mass of research and translational work being performed, iPSCs may very well be the cell type of choice for regenerative medicine in the future. Also, basic science questions, such as efficient differentiation protocols to the correct cell type for regenerating human tissues, the immune response of iPSC replacement therapy and genetic stability of iPSC-derived cells, are currently being investigated for future clinical applications.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons
Use and reproduction rights https://creativecommons.org/licenses/by/4.0/
Source of term cc
-- https://creativecommons.org/licenses/by/4.0/
546 ## - LANGUAGE NOTE
Language note English
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term clinical application
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term differentiation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term adult stem cell
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term human disease
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term immune response
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term induced pluripotent stem cells
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term genetic cell stability
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="http://www.mdpi.com/books/pdfview/book/163">http://www.mdpi.com/books/pdfview/book/163</a>
Access status 0
Public note DOAB: download the publication
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://directory.doabooks.org/handle/20.500.12854/50671">https://directory.doabooks.org/handle/20.500.12854/50671</a>
Access status 0
Public note DOAB: description of the publication

No items available.